不同性别前列腺患者PSA参考区间的系统评价

IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY
Rose Hall, Rue Ball, Elizabeth Bancroft, Rosalind Eeles, Alison May Berner
{"title":"不同性别前列腺患者PSA参考区间的系统评价","authors":"Rose Hall, Rue Ball, Elizabeth Bancroft, Rosalind Eeles, Alison May Berner","doi":"10.1111/bju.16825","DOIUrl":null,"url":null,"abstract":"ObjectivesTo determine mean/median serum total prostate‐specific antigen (PSA) levels in transgender women and non‐binary people with prostates (TWNBPP) who have received gender‐affirming hormone therapy (GAHT) or an orchidectomy. The secondary objective was to identify other quantitative information that influences PSA levels in this population.MethodsSystematic review of existing publications from primary studies published in English, excluding case reports and guidelines. Included studies: TWNBPP who have received GAHT/post‐orchidectomy, without a diagnosis of prostate pathology, with recorded serum PSA levels. MEDLINE and Embase databases were searched, up to July 2024.ResultsFour papers met the inclusion criteria, with 290 participants. Two papers measured the mean PSA level after 4 and 12 months of GAHT (mean [range] age 30 [18–45] years). A third paper measured the mean PSA level after a median of 9 years of GAHT (mean [range] age 40.1 [19–67] years). The fourth study measured 852 PSA levels in 210 participants receiving oestradiol therapy, over a 23‐year period (mean [range] age 60 [40–79] years). The mean and median PSA levels ranged from 0.020 to 0.525 ng/mL. Meta‐analysis of these data was unfeasible, due to low quantity, comparability, and quality of the studies.ConclusionsExisting data for serum PSA reference intervals for TWNBPP without prostate pathology were from four studies and cannot be used to make clinical recommendations. The evidence indicates that GAHT in TWNBPP lowers PSA levels from baseline, below expected levels for age‐matched cisgender controls. Not all TWNBPP over the age of 40 years should be offered PSA testing; however, those with a genetic predisposition, family history, or symptoms of prostate cancer, may request or be offered a PSA test. There are currently no clinical PSA thresholds to guide interpretation of PSA levels in TWNBPP when being evaluated for suspected prostate cancer or for those seeking PSA testing.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"38 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Systematic review of PSA reference intervals in the gender diverse population with prostates\",\"authors\":\"Rose Hall, Rue Ball, Elizabeth Bancroft, Rosalind Eeles, Alison May Berner\",\"doi\":\"10.1111/bju.16825\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ObjectivesTo determine mean/median serum total prostate‐specific antigen (PSA) levels in transgender women and non‐binary people with prostates (TWNBPP) who have received gender‐affirming hormone therapy (GAHT) or an orchidectomy. The secondary objective was to identify other quantitative information that influences PSA levels in this population.MethodsSystematic review of existing publications from primary studies published in English, excluding case reports and guidelines. Included studies: TWNBPP who have received GAHT/post‐orchidectomy, without a diagnosis of prostate pathology, with recorded serum PSA levels. MEDLINE and Embase databases were searched, up to July 2024.ResultsFour papers met the inclusion criteria, with 290 participants. Two papers measured the mean PSA level after 4 and 12 months of GAHT (mean [range] age 30 [18–45] years). A third paper measured the mean PSA level after a median of 9 years of GAHT (mean [range] age 40.1 [19–67] years). The fourth study measured 852 PSA levels in 210 participants receiving oestradiol therapy, over a 23‐year period (mean [range] age 60 [40–79] years). The mean and median PSA levels ranged from 0.020 to 0.525 ng/mL. Meta‐analysis of these data was unfeasible, due to low quantity, comparability, and quality of the studies.ConclusionsExisting data for serum PSA reference intervals for TWNBPP without prostate pathology were from four studies and cannot be used to make clinical recommendations. The evidence indicates that GAHT in TWNBPP lowers PSA levels from baseline, below expected levels for age‐matched cisgender controls. Not all TWNBPP over the age of 40 years should be offered PSA testing; however, those with a genetic predisposition, family history, or symptoms of prostate cancer, may request or be offered a PSA test. There are currently no clinical PSA thresholds to guide interpretation of PSA levels in TWNBPP when being evaluated for suspected prostate cancer or for those seeking PSA testing.\",\"PeriodicalId\":8985,\"journal\":{\"name\":\"BJU International\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-06-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BJU International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/bju.16825\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJU International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bju.16825","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的测定接受性别确认激素治疗(GAHT)或睾丸切除术的跨性别女性和非二元前列腺患者(TWNBPP)血清总前列腺特异性抗原(PSA)的平均/中位水平。次要目的是确定影响该人群PSA水平的其他定量信息。方法系统回顾现有英文发表的主要研究,排除病例报告和指南。纳入的研究:接受了GAHT/睾丸切除术后,没有前列腺病理诊断,有血清PSA水平记录的TWNBPP。检索截至2024年7月的MEDLINE和Embase数据库。结果符合纳入标准的论文4篇,共纳入受试者290人。两篇论文测量了GAHT治疗4个月和12个月后的平均PSA水平(平均[范围]年龄为30岁[18-45岁])。第三篇论文测量了gaat治疗中位9年后的平均PSA水平(平均[范围]年龄40.1岁[19-67]岁)。第四项研究测量了210名接受雌二醇治疗的参与者在23年期间的852个PSA水平(平均[范围]60[40-79]岁)。平均和中位PSA水平范围为0.020至0.525 ng/mL。由于研究的数量、可比性和质量较低,对这些数据进行Meta分析是不可行的。结论无前列腺病理的TWNBPP的血清PSA参考区间来自4项研究,不能用于临床推荐。有证据表明,在TWNBPP中,GAHT降低了PSA水平,低于年龄匹配的顺性别对照组的预期水平。并非所有40岁以上的TWNBPP都应该进行PSA检测;然而,那些有遗传易感性、家族史或前列腺癌症状的人,可能会要求或被提供PSA测试。目前没有临床PSA阈值来指导TWNBPP在评估疑似前列腺癌或寻求PSA检测时的PSA水平解释。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Systematic review of PSA reference intervals in the gender diverse population with prostates
ObjectivesTo determine mean/median serum total prostate‐specific antigen (PSA) levels in transgender women and non‐binary people with prostates (TWNBPP) who have received gender‐affirming hormone therapy (GAHT) or an orchidectomy. The secondary objective was to identify other quantitative information that influences PSA levels in this population.MethodsSystematic review of existing publications from primary studies published in English, excluding case reports and guidelines. Included studies: TWNBPP who have received GAHT/post‐orchidectomy, without a diagnosis of prostate pathology, with recorded serum PSA levels. MEDLINE and Embase databases were searched, up to July 2024.ResultsFour papers met the inclusion criteria, with 290 participants. Two papers measured the mean PSA level after 4 and 12 months of GAHT (mean [range] age 30 [18–45] years). A third paper measured the mean PSA level after a median of 9 years of GAHT (mean [range] age 40.1 [19–67] years). The fourth study measured 852 PSA levels in 210 participants receiving oestradiol therapy, over a 23‐year period (mean [range] age 60 [40–79] years). The mean and median PSA levels ranged from 0.020 to 0.525 ng/mL. Meta‐analysis of these data was unfeasible, due to low quantity, comparability, and quality of the studies.ConclusionsExisting data for serum PSA reference intervals for TWNBPP without prostate pathology were from four studies and cannot be used to make clinical recommendations. The evidence indicates that GAHT in TWNBPP lowers PSA levels from baseline, below expected levels for age‐matched cisgender controls. Not all TWNBPP over the age of 40 years should be offered PSA testing; however, those with a genetic predisposition, family history, or symptoms of prostate cancer, may request or be offered a PSA test. There are currently no clinical PSA thresholds to guide interpretation of PSA levels in TWNBPP when being evaluated for suspected prostate cancer or for those seeking PSA testing.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BJU International
BJU International 医学-泌尿学与肾脏学
CiteScore
9.10
自引率
4.40%
发文量
262
审稿时长
1 months
期刊介绍: BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信